NervGen Pharma Corp. Common stock
NASDAQ Capital MarketTotal Valuation
NervGen Pharma Corp. Common stock carries a market capitalization of 191.51M, placing it among publicly traded companies globally. Its enterprise value stands at 224.36M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 191.51M |
| Enterprise Value | 224.36M |
Share Statistics
NervGen Pharma Corp. Common stock currently has 106.41M shares outstanding.
| Shares Outstanding | 106.41M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 18.01 |
| P/TBV Ratio | 18.42 |
| P/FCF Ratio | -9.37 |
| P/OCF Ratio | -9.33 |
Financial Position
NervGen Pharma Corp. Common stock maintains a current ratio of 1.23, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.23 |
| Quick Ratio | 1.19 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -7,480.65 |
| Return on Assets (ROA) | -115.68 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
NervGen Pharma Corp. Common stock's stock has declined approximately -45.43326% over the past 52 weeks. The 50-day moving average sits at 1.87, while the 200-day moving average is 3.38.
| Beta (5Y) | N/A |
| 52-Week Price Change | -45.43326% |
| 50-Day Moving Average | 1.87 |
| 200-Day Moving Average | 3.38 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -32.25M, while operating income came in at -32.30M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -32.30M |
| Pretax Income | -61.96M |
| Net Income | -61.96M |
| EBITDA | -32.25M |
| EBIT | -32.30M |
| Earnings Per Share (EPS) | -0.75 |
Balance Sheet
Total book value stands at 17.28M, with working capital of 16.90M providing operational flexibility.
| Cash & Cash Equivalents | 86.79M |
| Total Debt | N/A |
| Net Debt | -86.79M |
| Equity (Book Value) | 17.28M |
| Book Value Per Share | 0.16 |
| Working Capital | 16.90M |
Cash Flow
NervGen Pharma Corp. Common stock produced -25.65M in operating cash flow over the past twelve months.
| Operating Cash Flow | -25.65M |
| Capital Expenditures | N/A |
| Free Cash Flow | -25.65M |
| FCF Per Share | -0.31 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -31.71 |
| FCF Yield | -10.68 |
Scores
NervGen Pharma Corp. Common stock posts an Altman Z-Score of -1.17, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -1.17 |